Immunodiagnostic Systems Hldgs (LON:IDH) , the Newcastle based specialist in-vitro diagnostics company, announced earlier today that it is enhancing its product development capabilities in vascular system diagnostics by acquiring 100% of the share capital of MGP Diagnostics AS, a Norwegian holding company that holds a patent portfolio relating to Matrix GLA protein (mGLA). The company has also entered into a research agreement with VitaK BV, the original developer of the patent portfolio and the leading global expert in mGLA biology, to assist in the proof of concept studies necessary to establish the clinical usefulness of the biomarker. There is a growing body of research evidence that indicates that mGLA is important in vascular calcification - the hardening of arteries and heart valves. Vascular calcification is a significant component of cardiovascular disease, and is prevalent in patients that have chronic kidney disease, especially those on kidney dialysis. These deals form part of Immunodiagnostic's stated strategy of moving into adjacent markets to its core Bone and Skeletal market, and could result in the development of additional products in its research only diagnostic kit markets as well as an eventual addition for its automated IDS-iSYS suite of assays targeted at clinical diagnosis.
IDH shares have appreciated by 130% over the last year. Immunodiagnostic Systems Holdings is currently graded B by LCF Research.
About the Author
LCF Research
0 comments
